Exciting discovery could 'stop cancer from killing people'

December 14, 2008

Metastasis is the ability of cancer cells to spread from a primary site, to form tumours at distant sites. It is a complex process in which cell motility and invasion play a fundamental role. Essential to our understanding of how metastasis develops is identification of the molecules, and characterisation of the mechanisms that regulate cell motility. Hitherto, these mechanisms have been poorly understood. Now, a team of researchers lead by Professor Marco Falasca at Barts and The London School of Medicine and Dentistry has shown not only that the enzyme phospholipase Cγ1 (PLCγ1) plays a crucial role in metastasis formation, but that down regulation of PLCγ1 expression is able to revert metastasis progression.

The team investigated the role of PLCγ1 in cell invasion and metastasis using different approaches to modulate its expression in highly invasive cancer cell lines. Their results showed that PLCγ1 is required for breast cancer cell invasion and activation of the protein Rac1. They revealed a functional link between PLCγ1 and Rac1 that provides insight into processes regulating cell invasion.

Professor Falasca explained: "Consistent with these data we detected an increase in PLC1 expression in metastases compared to primary tumours in breast cancer patients. Therefore PLCγ1 is critical for metastasis formation, and development and inhibition of this enzyme has a therapeutic potential in the treatment of metastasis dissemination."

"This is an exciting discovery. He has shown that turning off this molecule prevents metastasis. The simple fact is that if you stop metastasis, you stop cancer from killing people. We now need to focus on developing drugs that can block PLCγ1."
-end-
'Phospholipase Cγ1 is Required for Metastasis Development and Progression' is published in Cancer Research on Monday 15 December 2009.

The research was supported by The Association for International Cancer Research and by the European Commission FP6 program Apotherapy.

For further information contact:
Alex Fernandes
Communications Office
Queen Mary, University of London
Tel: 020 7882 7910
Email: a.fernandes@qmul.ac.uk

Notes to editors:

Barts and The London School of Medicine and Dentistry

Barts and The London School of Medicine and Dentistry - at Queen Mary, University of London - offers international levels of excellence in research and teaching while serving a population of unrivalled diversity amongst which cases of diabetes, hypertension, heart disease, TB, oral disease and cancers are prevalent, within east London and the wider Thames Gateway. Through partnership with our linked trusts, notably Barts and The London NHS Trust, and our associated University Hospital trusts - Homerton, Newham, Whipps Cross and Queen's - the School's research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.

At the heart of the School's mission lies world class research, the result of a focused programme of recruitment of leading research groups from the UK and abroad and a £100 million investment in state-of-the-art facilities. Research is focused on translational research, cancer, cardiology, clinical pharmacology, inflammation, infectious diseases, stem cells, dermatology, gastroenterology, haematology, diabetes, neuroscience, surgery and dentistry.

The School is nationally and internationally recognised for research in these areas, reflected in the £40 million it attracts annually in research income. Its fundamental mission, with its partner NHS Trusts, and other partner organisations such as CRUK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research.

Queen Mary University of London

Related Metastasis Articles from Brightsurf:

Cancer metastasis: From problem to opportunity
When cancer metastasizes, it often ends up in the lungs, where the new tumors unleash a cascade of chemical cues that thwart the body's immune response.

Resistance to immunosurveillance favors cluster cancer metastasis
Researchers at Baylor College of Medicine show that circulating cancer cell clusters are more resistant to NK-cell mediated destruction than single cancer cells, leading to more cluster metastasis.

Preventing metastasis -- An antibody with therapeutic potential
A receptor in the cell layer that lines the blood vessels from the inside stimulates both the formation of new blood vessels in tumors and metastasis.

Interactions between cancer cells and fibroblasts promote metastasis
In order to colonize other organs and grow into metastases, tumor cells that detach from the parent tumor need to manipulate their new microenvironment and create a 'metastatic niche'.

Protein AKAP8 suppresses breast cancer metastasis
A protein naturally produced in the body has been found to suppress breast cancer metastasis in animal models of human tumors.

Two cancer-causing genes work together to promote metastasis
Cancer-promoting genes MYC and TWIST1 co-opt immune system cells to enable cancer cells to spread, but blocking a key step in this process can help prevent the disease from developing.

Research sheds important light on the metastasis of neuroblastoma
Research sheds important light on the metastasis of neuroblastoma.

Predicting metastasis from primary tumor size
A new mathematical model uses the size of a cancer patient's initial, primary tumor to predict whether undetectable secondary tumors are already present.

Cancer metastasis: tumor plasticity counts
Publication in Cell Reports: Researchers at the Université Libre de Bruxelles (ULB) uncover the importance of tumor plasticity for cancer metastasis.

Scientists identify protein that promotes brain metastasis
A protein that breast, lung and other cancers use to promote their spread -- or metastasis -- to the brain, has been identified by a team led by Weill Cornell Medicine and New York-Presbyterian investigators.

Read More: Metastasis News and Metastasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.